IR&MEDIA

NEWS

REV-MED Launches New OnyRay Laser Device for Nail Fungus Treatment

관리자
3 Jan 2025
Views 148

7164c10fb36df.jpg

REV-MED, represented domestically by JL Medicores, has announced the release of its latest laser treatment device for nail fungus, OnyRay. This medical-grade laser device is designed to target onychomycosis (nail fungus) using a photochemical reaction that eradicates pathogens at their source.

A Revolutionary Approach to Nail Fungus Treatment

Unlike traditional athlete's foot, nail fungus penetrates the thick nail tissue, making medication less effective and requiring invasive procedures like nail removal in severe cases. OnyRay offers a non-invasive alternative, leveraging laser wavelengths to destroy fungal pathogens and provide faster therapeutic outcomes.

Key advantages of OnyRay:

  • Short Treatment Time: Each session lasts only 12–20 minutes.
  • Pain-Free Procedure: The treatment is non-invasive and causes no discomfort.
  • High Safety Standards: As a Class 3 medical device approved by the Korean Ministry of Food and Drug Safety (MFDS), OnyRay ensures no risk of burns.
  • Self-Sterilization Feature: Built-in disinfection prevents secondary infections.

Dual Wavelength Technology

OnyRay utilizes two selectable wavelengths for targeted treatment:

  • 405nm: Promotes reactive oxygen species (ROS) generation to eradicate fungal pathogens.
  • 635nm: Enhances blood circulation, activates cell regeneration, and boosts immune responses to bacterial detachment.

Meeting a Growing Need

JL Medicores highlighted the increasing prevalence of antifungal-resistant cases, making OnyRay a timely solution. “Laser therapy offers a pain-free, liver-safe alternative without the risks of systemic antifungal medications. It is also accessible to patients concerned about insurance costs,” said a company representative.

JL Medicores is currently seeking domestic distributors to expand access to OnyRay and its groundbreaking laser treatment capabilities.


Source : Rapportian (https://www.rapportian.com)

0 0